FOR RESEARCH USE ONLY
Predominantly preclinicalSkin research

GHK-Cu

Copper-binding tripeptide researched for collagen synthesis, skin remodelling and hair density.

01Collagen remodelling02Copper biology03Skin & follicle models
Molecular signature / ghk-cu
Structural identity

Naturally occurring tripeptide complexed with Cu²⁺

Also known as

Copper tripeptide-1 · Glycyl-L-histidyl-L-lysine copper

Research-use context

In-vitro and laboratory information only. No human-use recommendation.

Guide contentsOpen in calculator
Section 01

Compound briefing

GHK-Cu is a naturally occurring copper-binding tripeptide (Gly-His-Lys complexed with Cu²⁺), first isolated from human plasma in 1973. Endogenous plasma levels decline from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 — a decline correlated with reduced tissue-repair capacity. Transcriptome analysis shows GHK-Cu modulates expression of over 4,000 genes involved in tissue remodelling.

The research question

GHK-Cu sits at the intersection of copper chemistry and tissue signalling. Its research value lies in extracellular-matrix remodelling, wound models and changes in gene expression, with topical and systemic work requiring separate interpretation.

Section 02

Mechanism & research themes

Acts as a biological signal of tissue damage — triggering stem cell activation, chemoattraction of repair cells, upregulation of collagen I/III/IV synthesis and broad transcriptome-level remodelling. Copper chelation also drives potent antioxidant activity via SOD stimulation.

01

Upregulated type I/III collagen synthesis with improved skin elasticity and density

02

Accelerated wound contraction, re-epithelialisation and angiogenesis

03

Increased follicle size and extended anagen phase in hair-growth studies

04

Reversal of aged-skin gene expression toward younger transcriptomic profiles

05

Potent free-radical scavenging via copper-mediated SOD activity

06

Emerging neuroprotection and lung-tissue repair signals in animal models

These are research themes reported across the literature, not established benefits or indications.

Section 03

Evidence assessment

Predominantly preclinical

Mechanistic, animal and dermatological studies provide a broad rationale, but study quality and formulation vary considerably. Gene-expression findings do not by themselves establish clinical outcomes.

What to look for

Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.

What not to assume

A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.

Section 04

Protocol literature

Topical (most common): 1–5% peptide or cream, once or twice daily to target area. Injectable research protocols: 1–2mg subcutaneously or intradermally, 2–3× weekly to target area; systemic SC at 1–3mg/day. Cycles typically run 8–12 weeks.

Reported persistence

Plasma approximately 0.5–1 hour; tissue residence and biological effect persists for days to weeks.

Calculator starting point

2 mg per reference dose

3 doses per week · 10-week cycle

5 mL default reconstitution volume

Injectable research: 1–2 mg SC 2–3×/week, or 1–3 mg/day systemic.

Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.

Calculate GHK-Cu
Section 05

Laboratory handling

Reconstitution reference

Reconstitute a 50mg vial with 5mL bacteriostatic water for a 10mg/mL working concentration. The solution will appear blue-green — this is the copper complex and is expected.

Storage reference

Lyophilised: room temperature acceptable short-term; 2–8°C for long-term (stable 12–24 months). Reconstituted: 2–8°C, protect from direct light, use within 60 days. Blue-green colour does not indicate degradation.

Minimum documentation standard

  • Record the lot identifier and review its matching analytical documentation.
  • Use aseptic technique and record diluent, final volume and calculated concentration.
  • Label preparation date, storage conditions and any light or freeze–thaw restrictions.
  • Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Section 06

Limitations & safety

L1

Theoretical copper-accumulation risk at chronic high systemic doses — avoid in Wilson's disease or copper-metabolism disorders.

L2

Mild transient redness or warmth at topical application sites, particularly at >5% concentrations.

L3

In-vitro pro-oxidant activity has been observed at very high concentrations (>100µM) — well above therapeutic ranges, but relevant for high-dose injection protocols.

Research use only

This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.

Continue reading

Related field notes

Back to all field notes

Welcome to HV Labs

Please confirm your age to continue.

For research use only